N-Acetyl Semax Amidate.
N-Acetyl Semax Amidate is a terminally modified analogue of Semax — derived from the ACTH(4-7) fragment — with N-terminal acetylation and C-terminal amidation conferring enhanced enzymatic stability and blood-brain barrier penetration.
- Key Signals
- Cognition · Neuroprotection · BDNF
- Origin
- Synthetic (ACTH(4-7) analogue)
- Investigator
- Myasoedov et al. (RAS), 1980s
- Class
- N-acetylated, C-amidated heptapeptide
- Status (UAE)
- Research compound (off-label)
ACTH's Cognitive Fragment, Engineered to Last
Semax is developed from the ACTH(4-7) fragment at the Russian Academy of Sciences in the 1980s, gaining approval as a nasal nootropic in Russia.
N-terminal acetylation and C-terminal amidation are applied to produce a more metabolically stable analogue with enhanced blood-brain barrier penetration.
The modified form attracts research interest for neuroprotection and BDNF-mediated cognitive enhancement requiring greater CNS bioavailability.
Seven residues, BDNF on demand.
Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂
C₃₉H₅₄N₁₀O₁₀S · MW 854.9 Da
The N-acetyl and C-amidate termini protect against exopeptidase cleavage — the defining modifications over Semax — preserving its ACTH-derived BDNF-upregulating receptor interactions at higher CNS exposure.
Strong BDNF signal, no analogue-specific trials.
Strong BDNF-upregulation evidence from Semax; no independent trials exist for this modified analogue.
- BDNF upregulation (strong)
- NGF upregulation confirmed
- Neuroprotection in ischemia
- Memory consolidation improved
- Neuroinflammation attenuated
- Cognitive performance improved
- Stroke recovery supported (RU)
- Attention and recall enhanced
- No independent trials for analogue
- Longer action vs unmodified Semax
- Superior BBB penetration (proposed)
- Depression adjunct potential
- Anxiolytic effects emerging
Sign in to view the full research brief.
Mechanism deep-dive and research dosing protocols — available to registered researchers. It's free and takes under a minute.
Semax's Approval Doesn't Transfer Here
In the UAE, research-grade peptides occupy a defined regulatory category distinct from licensed medicines. Compounds sold under this classification — including those offered by Dubai Peptides — are intended exclusively for qualified research applications, not for human administration.
N-Acetyl Semax Amidate has no regulatory approval in any jurisdiction — including Russia, where existing approval covers only the unmodified Semax nasal spray formulation, a chemically distinct product. No IND or equivalent filing has been submitted for this modified analogue in the US, EU, or UAE. Its terminal acetyl and amidate modifications make it a separate compound from any approved parent.
Myasoedov's group at the Russian Academy develops Semax from the ACTH(4-7) fragment, establishing its nootropic and neuroprotective profile.
Terminal acetylation and amidation are applied to the Semax backbone, producing an analogue with enhanced enzymatic resistance and CNS bioavailability.
N-Acetyl Semax Amidate enters the research-peptide market as a distinct, unapproved compound — no regulatory body has reviewed it independently.